Front | Back |
GCC-DR
|
Gulf Central Committee for Drug Registration-1999-Middle East States: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates
|
EMA
|
European Medicine Agency (formerly EMEA)-27 countries plus Norway and Iceland-Scientific and quality assessment of Drug safety, efficacy and manufacturing quality
|
CA
|
Competent authority
|
MAH
|
Marketing Authority Holder
|
QP
|
Qualified Person-MAH legal responsibility to have QP for drug batch release (including EU, Canada, Switz, AUS, Jp, New Zealand)-MAH legal responsibility to have QP for Pharmacovigilance
|
OECD
|
Organization of Economic Cooperation and Development-"Principles of GLP---Outline for GLP
|
PLM
|
Product Lifecycle Management-management of product life cycle, from conception, through design and manufacturing, to launch, service and disposal.-MAH needs to track changes, archive information, update CA and evaluate and obtain approval if changes have significant impact on product performance
|
PVP
|
PharmacoVigilance Plan:-Activities related to detection, assessment, understanding and prevention of adverse events, or other drug-related problems-MAH and CA responsibilities
|
FMEA
|
Failure Mode Effect Analysis
|